

PARMAX PHARMA LIMITED

Financial statement for the quarter ended 30.09.2013

1	Net Sale / Income from Operation			
	Commission received	-		
	Other income	-		
	(A)		-	
2	Other Income	-	-	
3	Total Expenditure			
	(a) Increase / Decrease in stock		-	
	(b) Purchase of Shares & Securities		-	
			-	
	(c) Staff Cost			
	Salary & Directors Remuneration	-		
	Staff Welfare	-	-	
	(d) Other Expenditure		-	
4	(B)		-	
	Profit (+ or -) before Dep.(A-B)			-
	Depreciation			-
	Profit (+ or -) after Dep.			-

Unaudited Financial Results (Provisional) for the Quarter Ended 30.09.2013

Sr. No	Particulars	3 months ended 30.09.2013	Corresponding 3 months ended 30.09.2012	Six month ended 30.09.2013	Corresponding Six month ended 30.09.2012	Year Ended 31.03.2013
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	a Net Sales/Income from Operations	-	-	-	-	-
	b Other operating Income	-	-	-	-	-
	Total Income	-	-	-	-	-
2	Expenditure					
	a : (Increase)/Decrease in Stock-in-Trade	-	-	-	-	-
	b : Consumption of Raw Material	-	-	-	-	-
	c : Purchase of traded goods	-	-	-	-	-
	d : Employees Cost	-	-	-	-	-
	e : Depreciation	-	-	-	-	-
	f : Other Expenditure	-	12,500.00	35,204.00	25,000.00	50,000.00
	g Total	-	12,500.00	35,204.00	25,000.00	50,000.00
3	Profit from Operations before other Income, Interest and Exceptional Items (1-2)	-	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
4	Other Income	-	-	-	-	-
5	Profit before Interest and Exceptional Items (3+4)	-	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
6	Interest	-	-	-	-	-
7	Profit after interest but before exceptional items (5-6)	-	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
8	Exceptional Items	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7+8)	-	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
10	Tax Expenses	-	-	-	-	-
11	Net Profit from Ordinary Activities after Tax (9-10)	-	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
12	Extraordinary item	-	-	-	-	-
13	Net Profit for the period (11-12)	-	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
14	Paid-up Equity Share Capital-[Face Value. Rs 10]	39,020,500.00	39,020,500.00	39,020,500.00	39,020,500.00	39,020,500.00
15	Reserve excluding revaluation reserve	-	-	-	-	578,089.00
16	Basic & Diluted EPS	-	-	-	-	-
17	Public Shareholding					
	Number of Shares					
	% of Shareholding					
18	Promoters and promoter group Shareholding					
	a Pledge / Encumbered					
	Number of Shares	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of the total Share Capital of the Company)	NIL	NIL	NIL	NIL	NIL
	b Non encumbered					
	Number of Shares					
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)					
	Percentage of Shares (as a % of the total Share Capital of the Company)					

Notes :

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on
- There were no investors complaints during the quarter ended 30th Sep 2013
- Previous years figures has been regroup / rearranged wherever necessary.

PARMAX PHARMA LIMITED

Alkesh M. Gopani
Director



Place Hadamtala (Rajkot)

Date:

Clause 41 of the Listing Agreement For companies (Other than Banks)

	Stadalone / Consolidated Statement of Assets and Liabilities Particulars	As at (30-09-13)	As at (31/03/13)
A	EQUITY AND LIABILITIES		
1	Shareholder's funds		
	(a) Share capital	39020500	39020500
	(b) Reserves and surplus	542,885	578,089
	© Money received against share warrants	0	0
	Sub- total - Shareholder's funds	39563385	39598589
	Share application money pending allotment	0	0
2			
3	Minority interest*	0	0
4	Non-current liabilities		
	(a) Long-term borrowings	9094469	9034265
	(b) Deferred tax liabilities (net)	0	0
	© Other long-term liabilities	0	0
	(d) Long-term provisions	0	0
	Sub-total-Non-current liabilities	9094469	9034265
5	Current liabilities		
	(a) Short-term borrowings	0	0
	(b) Trade payables	646603	647603
	(c) Other current liabilities	1760	1760
	(d) Short-term provisions	93000	108000
	Sub-total- Current liabilities	741363	757363
	TOTAL - EQUITY AND LIABILITIES	49399217	49390217
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	25331120	25331120
	(b) Goodwill on consolidation*	0	0
	(c) Non-current investments	6000	6000
	(d) Deferred tax assets (net)	0	0
	(e) Long-term loans and advances	734400	734400
	(f) Other non-current assets	8524466	8524466
	Sub-total-Non-current assets	34595986	34595986
2	Current assets		
	(a) Current investments	0	0
	(b) Inventories	0	0
	© Trade receivables	90000	90000
	(d) Cash and cash equivalents	2747112	2722713
	(e) Short-term loans and advances	11966119	11981518
	(f) Other current assets	0	0
	Sub-total-Current assets	14803231	14794231
	TOTAL - ASSETS	49399217	49390217

ARVIND A. THAKKAR & CO
CHARTERED ACCOUNTANTS

Arvind A. Thakkar
B.Com., F.C.A.

Phone : 079 - 27543655 / 50
Ground Floor, Trupti Apartments,
Behind Old High Court,
Navrangpura, Ahmedabad-380 009.
Email : aathakkar47@gmail.com
Mobile : 9825484365

Date :

Auditor's Limited Review Report

On Unaudited Financial Results

To
The Board of Directors,
Parmax Pharma Limited


We have reviewed the accompanying statement of unaudited financial results of **PARMAX PHARMA LIMITED** for the quarter ended on **30th September 2013**. This statement is the responsibility of the Company's Management.

A review of the interim financial information consist principally of applying analytical procedures for the financial data and making enquiries of persons responsible for financial and accounting matters. It is substantially less in scope than audit conducted in accordance with the generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly we do not express such an opinion. Further our review was mainly in regard to the figures of quarter ended 30th September 2013.

During our review we have noticed that:

There are small differences between amounts as per published results and corresponding figures as per the accounts (which are however within the allowed limit of 10% or Rs. 10 lacs, whichever is higher).

Except this nothing has come to our notice that causes us to believe that the accompanying statements of unaudited financial results have not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contain any material misstatement.



Place: Ahmedabad
Date: 10/10/2013

FOR ARVIND A. THAKKAR & CO.
CHARTERED ACCOUNTANTS

(Signature)
A. A. THAKKAR
(SOLE PROPRIETOR)

Membership No. 014334